top of page

Micro RNAs (miRNAs) & epigenetic modications in glioblastoma and Neuroendocrine tumors (NETs)

Jan 25, 2023
2 min read

Updated: Apr 4, 2023


Authors: Miss. Ruchita Karmakar

Amity University, Kolkata India

Co-Author: Mr. Narendra Singh Amity University, Kolkata India


Email: ruchitakarmakar@gmail.com

Volume: BRAINCANCER2023_CN28_AA03


Abstract:

Glioblastoma is a type of brain cancer. It’s the most common type of malignant brain tumor among adults. And it is usually very aggressive, which means it can grow fast and spread quickly.Epigenetic factors play an important role in gliomagenesis, are strong predictors of outcome, and are important determinants for the resistance to radio- and chemotherapy. The latest addition to the epigenetic machinery is the noncoding RNA (ncRNA), that is, RNA molecules that are not translated into a protein and that exert their function by base pairing with other nucleic acids in a reversible and nonmutational mode.MicroRNAs (miRNAs) are a class of non-coding RNAs with an average 22 nucleotides in length that play important roles in regulating gene expression. MicroRNAs are epigenetic regulatory molecules that possessing multiple targets have a profound impact on cell physiology and pathology. MicroRNAs are players of the “epigenetic orchestra” that fine-tune the coordinate transcription of the genetic information. It is quite clear that control exerted by miRNA is extraordinary complex, that indeed a single miRNA can bind many genes, and that each gene can be recognized by many miRNAs in an extremely complex direct and indirect regulatory circuitry. Obviously, mastering this network could have dramatic effects on cell behavior. The response to treatment in GB patients is variable and probably depends from tumor heterogeneity that originates from genetic and epigenetic alterations which can influence the behavior of the disease. In this respect, the relation between miRNA and chemo- and radiotherapy has been extensively exploited to search for new possible therapeutic targets or to predict and improve the response to treatment.







Brain Cancer 2024
February 4, 2024, 8:00 – 11:59 PM GMT+5:30Virtual Live Conference
Register Now

bottom of page